Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases
- Author:
Pin-Nan CHENG
1
;
Wen-Jone CHEN
;
Charles Jia-Yin HOU
;
Chih-Lin LIN
;
Ming-Ling CHANG
;
Chia-Chi WANG
;
Wei-Ting CHANG
;
Chao-Yung WANG
;
Chun-Yen LIN
;
Chung-Lieh HUNG
;
Cheng-Yuan PENG
;
Ming-Lung YU
;
Ting-Hsing CHAO
;
Jee-Fu HUANG
;
Yi-Hsiang HUANG
;
Chi-Yi CHEN
;
Chern-En CHIANG
;
Han-Chieh LIN
;
Yi-Heng LI
;
Tsung-Hsien LIN
;
Jia-Horng KAO
;
Tzung-Dau WANG
;
Ping-Yen LIU
;
Yen-Wen WU
;
Chun-Jen LIU
Author Information
- Publication Type:Review
- From:Clinical and Molecular Hepatology 2024;30(1):16-36
- CountryRepublic of Korea
- Language:English
- Abstract: Metabolic dysfunction-associated fatty liver disease (MAFLD) is an increasingly common liver disease worldwide. MAFLD is diagnosed based on the presence of steatosis on images, histological findings, or serum marker levels as well as the presence of at least one of the three metabolic features: overweight/obesity, type 2 diabetes mellitus, and metabolic risk factors. MAFLD is not only a liver disease but also a factor contributing to or related to cardiovascular diseases (CVD), which is the major etiology responsible for morbidity and mortality in patients with MAFLD. Hence, understanding the association between MAFLD and CVD, surveillance and risk stratification of MAFLD in patients with CVD, and assessment of the current status of MAFLD management are urgent requirements for both hepatologists and cardiologists. This Taiwan position statement reviews the literature and provides suggestions regarding the epidemiology, etiology, risk factors, risk stratification, nonpharmacological interventions, and potential drug treatments of MAFLD, focusing on its association with CVD.
